Eleven new epilepsy genes point to potential new ways to prevent seizures
Epilepsy researchers from around the world have examined the DNA of more than 45 000 people, leading to the discovery of 11 genes associated with the disorder and pointing the way to drugs that might benefit millions of patients who do not respond to existing treatments.
Researchers led by University of Melbourne clinical neurologist Sam Berkovic compared the DNA of more than 15 000 people with epilepsy to the DNA of 30 000 control people without the disorder.
The results, published today in Nature Communications, tripled the number of known genetic associations for epilepsy and – importantly – implicated 11 new genes which have a number of different functions in the human body, including:
Regulating interactions between brain cells
Converting vitamin-B6 into its active form, potentially making some forms of epilepsy easily treatable
How proteins are made from the blueprint of genes.
The researchers found most available anti-epileptic drugs directly target one or more of these genes, but they also identified an additional 166 drugs that do the same.
Professor Berkovic, who is based at Austin Health, said the discovery was significant because with current treatment options a third of the 65 million epilepsy patients worldwide cannot be effectively treated to be free of seizures.
“These drugs we’ve identified already exist but may show promise for treating epilepsy as they directly target the genetic basis of the disease,” Professor Berkovic said.
“With our findings, we hope that in the future more people with epilepsy will achieve seizure freedom.”
Professor Berkovic said epilepsy’s cause had long been shrouded in mystery.
“We now understand that the cause is largely genetic, but little was known about the specific genes responsible for the most common forms of the disorder,” he said.
The next step would be replicating these results in an even larger sample, which is underway, and then drilling down on specific groups of patients and the genes that influence their type of epilepsy to trial new therapies, Professor Berkovic said.